EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

VRK3 promotes KSHV infection by suppressing the antiviral type I interferon response

Caroline J Yu, Blossom Damania iD

PLOS Pathogens · 27.07.2026 · 22 (7) · e1014400

DOI: 10.1371/journal.ppat.1014400 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 27.07.2026. Verfasst von Caroline J Yu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Lineberger Cancer Comprehensive Center, University of North Carolina, Chapel Hill, North Carolina, United States of America. Hauptthemen laut MEDLINE: Herpesvirus 8, Human, Protein Serine-Threonine Kinases, Interferon Type I, Herpesviridae Infections. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kaposi sarcoma-associated herpesvirus (KSHV) is an oncogenic gammaherpesvirus that is associated with several human malignancies, and primary infection by KSHV can activate both DNA and RNA sensing pathways. Host innate immunity is a rapid, first-line defense against foreign pathogens, where pattern recognition receptors detect virus-associated antigens and activate the type I interferon response to prime the cell to an antiviral state to limit viral infections. However, viruses such as gammaherpesviruses, have evolved mechanisms to co-opt host factors to antagonize these pathways to promote persistent infection. The cellular vaccinia-related kinase (VRK) family is a trio of serine/threonine kinases, VRK1, VRK2 and VRK3, named for their homology to the vaccinia virus B1 kinase. The VRKs are involved in many cellular processes, including nuclear envelope assembly during mitosis and the DNA damage response. However, the role of the VRKs in KSHV infection and innate immunity has not previously been explored. We found that VRK3 is upregulated in response to KSHV primary infection of endothelial cells. VRK3 is also upregulated during KSHV reactivation from latency. Knockdown of VRK3 limited KSHV primary infection and lytic reactivation and resulted in increased activation of TBK1 and IRF3 and subsequent upregulation of interferon stimulated genes. Overexpression of VRK3 reversed this phenotype. Furthermore, we are also the first to demonstrate that VRK3 is a negative regulator of the interferon response even in the absence of viral infection. Collectively, our data highlight the importance of the host factor, VRK3, as a novel suppressor of the type I interferon response during the KSHV viral lifecycle.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Herpesvirus 8, HumanProtein Serine-Threonine KinasesInterferon Type IHerpesviridae InfectionsHumansImmunity, Innate

Substanzen

Protein Serine-Threonine KinasesInterferon Type I

Autor:innen und Institutionen

  • Lineberger Cancer Comprehensive Center, University of North Carolina, Chapel Hill, North Carolina, United States of America.
  • Department of Microbiology & Immunology, University of North Carolina, Chapel Hill, North Carolina, United States of America.

ORCID-Profile: Blossom Damania

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • NIH

Zitieren

APA

Yu, C. J., & Damania, B. (2026). VRK3 promotes KSHV infection by suppressing the antiviral type I interferon response. PLOS Pathogens, 22(7), e1014400. https://doi.org/10.1371/journal.ppat.1014400

Vancouver

Yu CJ, Damania B. VRK3 promotes KSHV infection by suppressing the antiviral type I interferon response. PLOS Pathogens. 2026;22(7):e1014400. doi:10.1371/journal.ppat.1014400

BibTeX
@article{Yu2026,
  author = {Yu, Caroline J and Damania, Blossom},
  title = {VRK3 promotes KSHV infection by suppressing the antiviral type I interferon response},
  journal = {PLOS Pathogens},
  year = {2026},
  volume = {22},
  number = {7},
  pages = {e1014400},
  doi = {10.1371/journal.ppat.1014400}
}
Kostenlos starten →